U.S., July 25 -- ClinicalTrials.gov registry received information related to the study (NCT07725432) titled 'Topical Ruxolitinib Evaluation in Immune-related Vitiligo-like Depigmentation' on May 31, 2024.
Brief Summary: White spot disease is a common side effect on the skin in the context of cancer treatments with immunotherapies. There is no standard therapy yet for white spot caused by cancer therapies. There is already research in humans on the treatment of white spot disease. Previous human studies with ruxolitinib cream have shown that approximately 30% of patients with white spot disease have achieved a 75% improvement (re-pigmentation) of their affected areas after 24 weeks and approximately 50% of patients have achieved a 75% impro...